Gene Biotherapeutics, Inc. (CRXM)

USD 0.0

(9900.0%)

Total Debt Summary of Gene Biotherapeutics, Inc.

  • Gene Biotherapeutics, Inc.'s latest annual total debt in 2022 was - USD , down 0.0% from previous year.
  • Gene Biotherapeutics, Inc.'s latest quarterly total debt in 2022 FY was - USD , down 0.0% from previous quarter.
  • Gene Biotherapeutics, Inc. reported annual total debt of - USD in 2021, down -100.0% from previous year.
  • Gene Biotherapeutics, Inc. reported annual total debt of 1.26 Million USD in 2020, up 12.4% from previous year.
  • Gene Biotherapeutics, Inc. reported quarterly total debt of - USD for 2021 FY, down -100.0% from previous quarter.
  • Gene Biotherapeutics, Inc. reported quarterly total debt of 1.26 Million USD for 2020 FY, up 12.4% from previous quarter.

Annual Total Debt Chart of Gene Biotherapeutics, Inc. (2022 - 1995)

Historical Annual Total Debt of Gene Biotherapeutics, Inc. (2022 - 1995)

Year Total Debt Total Debt Growth
2022 - USD 0.0%
2021 - USD -100.0%
2020 1.26 Million USD 12.4%
2019 1.12 Million USD 5.2%
2018 1.06 Million USD -13.43%
2017 1.23 Million USD 17.23%
2016 1.05 Million USD 11.01%
2015 946.14 Thousand USD 37.43%
2014 688.43 Thousand USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD -100.0%
2008 4.03 Million USD -14.55%
2007 4.72 Million USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%
2004 - USD 0.0%
2003 - USD 0.0%
2002 - USD 0.0%
2001 - USD 0.0%
2000 - USD 0.0%
1999 - USD 0.0%
1998 - USD -100.0%
1997 5.02 Million USD -2.98%
1996 5.17 Million USD 1.57%
1995 5.09 Million USD 0.0%

Peer Total Debt Comparison of Gene Biotherapeutics, Inc.

Name Total Debt Total Debt Difference
America Great Health 1.87 Million USD 100.0%
Ampio Pharmaceuticals, Inc. 274 Thousand USD 100.0%
Aridis Pharmaceuticals, Inc. 6.13 Million USD 100.0%
Biora Therapeutics, Inc. 47.42 Million USD 100.0%
Bio-Path Holdings, Inc. 113 Thousand USD 100.0%
Better Therapeutics, Inc. 14.88 Million USD 100.0%
Calithera Biosciences, Inc. 1.66 Million USD 100.0%
Comera Life Sciences Holdings, Inc. 775.04 Thousand USD 100.0%
eFFECTOR Therapeutics, Inc. 19.44 Million USD 100.0%
Eloxx Pharmaceuticals, Inc. 13.38 Million USD 100.0%
Evelo Biosciences, Inc. 51.13 Million USD 100.0%
Evolutionary Genomics, Inc. 3.74 Million USD 100.0%
Finch Therapeutics Group, Inc. 30.12 Million USD 100.0%
Galera Therapeutics, Inc. 152.29 Million USD 100.0%
Innovation1 Biotech Inc. 228.99 Thousand USD 100.0%
Kiromic BioPharma, Inc. 15.54 Million USD 100.0%
Molecular Templates, Inc. 12.23 Million USD 100.0%
Navidea Biopharmaceuticals, Inc. 2.43 Million USD 100.0%
NexImmune, Inc. 68.8 Thousand USD 100.0%
Orgenesis Inc. 22.62 Million USD 100.0%
Panbela Therapeutics, Inc. 5.19 Million USD 100.0%
Point of Care Nano-Technology, Inc. - USD NaN%
PaxMedica, Inc. Common Stock - USD NaN%
Scopus BioPharma Inc. - USD NaN%
Sorrento Therapeutics, Inc. 134.5 Million USD 100.0%
Statera Biopharma, Inc. 16.26 Million USD 100.0%
TRACON Pharmaceuticals, Inc. 968 Thousand USD 100.0%
Trevena, Inc. 35.23 Million USD 100.0%
Vaxxinity, Inc. 15.16 Million USD 100.0%
Vaccinex, Inc. 247 Thousand USD 100.0%
Vicapsys Life Sciences, Inc. 353.86 Thousand USD 100.0%
Viracta Therapeutics, Inc. 25.55 Million USD 100.0%
ZIVO Bioscience, Inc. 346.34 Thousand USD 100.0%